Tenon Medical Announces Fusion Results in First Patients Reaching 12-Month Follow Up in an IRB Approved, Multi-Centered, Post-Market Study Utilizing the Catamaran SI Joint Fusion System
Portfolio Pulse from Benzinga Newsdesk
Tenon Medical, Inc. (NASDAQ:TNON) announced significant progress in a post-market study of its Catamaran SI Joint Fusion System for treating sacroiliac joint disorders. Preliminary results at 12-month follow-up show 100% fusion response, marked improvements in pain scores, disability, and high patient satisfaction. Study enrollment is expected to complete soon, with patients evaluated up to 24 months.
March 26, 2024 | 12:11 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tenon Medical's positive preliminary results from the Catamaran SI Joint Fusion System study show 100% fusion response and high patient satisfaction at 12-month follow-up.
The positive preliminary results from the study of Tenon Medical's Catamaran SI Joint Fusion System indicate a successful product performance and high patient satisfaction. This could lead to increased demand for the product, potentially boosting the company's revenue and positively impacting its stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100